Neurona Therapeutics
SOUTH SAN FRANCISCO, CA · Biotechnology · 91 employees
Neurona is a biotherapeutics company developing neural cell therapies with single-dose curative potential for the treatment of chronic neurological disorders. Based on a novel neural cell lineage pioneered by the company’s scientific founders, Neurona has built a robust regenerative platform and is developing neuronal, glial, and gene-edited cell therapy candidates that provide long-term repair of
Funding history
- Funding Round — $101.7M — Apr 2025
- Funding Round — $120.0M — Feb 2024
- Funding Round — $72.0M — Dec 2022
- Series seed — $72.0M — Feb 2022
- Funding Round — $28.3M — Mar 2021
Recent signals
- Nov 18, 2025: Neurona Therapeutics Appoints Eduardo Dunayevich as Chief Medical Officer
- Apr 04, 2025: Raised $101.7M
- Apr 03, 2025: Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline
- Oct 15, 2024: Launched Neurizon Therapeutics Limited, formerly PharmAust Limited, announces its name change and commitment to advancing treatments for neurodegenerative diseases.
- Jun 11, 2024: Neurona Therapeutics Appoints Manher (AJ) Joshi, M.D. as Chief Medical Officer
- Feb 13, 2024: Raised $120.0M
- Dec 23, 2022: Raised $72.0M
- Feb 22, 2022: Raised $72.0M in Series seed
See plans & pricing → Track Neurona Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.